KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biomarin Pharmaceutical (BMRN) Debt to Equity (2016 - 2024)

Biomarin Pharmaceutical's Debt to Equity history spans 14 years, with the latest figure at $0.09 for Q2 2024.

  • For the quarter ending Q2 2024, Debt to Equity changed N/A year-over-year to $0.09, compared with a TTM value of $0.09 through Jun 2024, changed N/A, and an annual FY2023 reading of $0.1, changed N/A over the prior year.
  • Debt to Equity for Q2 2024 was $0.09 at Biomarin Pharmaceutical, down from $0.1 in the prior quarter.
  • The five-year high for Debt to Equity was $0.11 in Q2 2020, with the low at $0.01 in Q3 2022.
  • Average Debt to Equity over 5 years is $0.05, with a median of $0.01 recorded in 2022.
  • Year-over-year, Debt to Equity surged 3310.96% in 2020 and then crashed 93.45% in 2021.
  • Tracing BMRN's Debt to Equity over 5 years: stood at $0.09 in 2020, then plummeted by 87.75% to $0.01 in 2021, then crashed by 45.21% to $0.01 in 2022, then surged by 1509.98% to $0.1 in 2023, then dropped by 6.15% to $0.09 in 2024.
  • Per Business Quant, the three most recent readings for BMRN's Debt to Equity are $0.09 (Q2 2024), $0.1 (Q1 2024), and $0.1 (Q4 2023).